Results 11 to 20 of about 3,389,488 (311)
Scientific Reports, 2021 Patients with coronavirus disease-19 (COVID-19) are at high risk for thrombotic arterial and venous occlusions. However, bleeding complications have also been observed in some patients.
Yu Zuo +9 more
doaj +2 more sources
Regulation of plasminogen activation on cell surfaces and fibrin
Journal of Thrombosis and Haemostasis, 2018 The fibrinolytic system dissolves fibrin and maintains vascular patency. Recent advances in imaging analyses allowed visualization of the spatiotemporal regulatory mechanism of fibrinolysis, as well as its regulation by other plasma hemostasis cofactors.
T. Urano, F. Castellino, Yuko Suzuki
exaly +2 more sources
Plasminogen Activator Inhibitor Type‐1 as a Regulator of Fibrosis
Journal of Cellular Biochemistry, 2018 Maryam Boshtam, Rui Dinis, Hamed Mirzaei
exaly +2 more sources
Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 complex as a serum biomarker for COVID-19 [PDF]
Frontiers in Immunology, 2023 Patients with coronavirus disease-2019 (COVID-19) have an increased risk of thrombosis and acute respiratory distress syndrome (ARDS). Thrombosis is often attributed to increases in plasminogen activator inhibitor-1 (PAI-1) and a shut-down of ...
Tetiana Yatsenko +12 more
doaj +2 more sources
Involvement of plasminogen activator inhibitor-1 and its related molecules in atrial fibrosis in patients with atrial fibrillation [PDF]
PeerJ, 2021 Atrial fibrillation is the most common form of cardiac arrhythmia. Atrial fibrosis is a significant feature of atrial fibrillation though its mechanism is not well understood.
Qiaoqiao Li +11 more
doaj +2 more sources
International Journal of Molecular Sciences, 2021 Plasminogen activator inhibitor-1 (PAI-1) is the main physiological inhibitor of plasminogen activators (PAs) and is therefore an important inhibitor of the plasminogen/plasmin system.
M. Sillen, P. Declerck
semanticscholar +1 more source
Incidence of Hemorrhagic Complications among Patients Treated with Thrombolytic in Erbil City, Iraq [PDF]
Al-Anbar Medical Journal, 2020 Background: Recombinant tissue-type plasminogen activator is an option of treatment for suspected occlusive vascular thrombi and its sequel (transmural myocardial infarction, pulmonary embolism, and ischemic stroke). The most important concern associated
Ahmed F. Hammad +2 more
doaj +1 more source
The Plasminogen–Activator Plasmin System in Physiological and Pathophysiological Angiogenesis
International Journal of Molecular Sciences, 2021 Angiogenesis is a process associated with the migration and proliferation of endothelial cells (EC) to form new blood vessels. It is involved in various physiological and pathophysiological conditions and is controlled by a wide range of proangiogenic ...
A. Ismail, B. Shaker, K. Bajou
semanticscholar +1 more source
Histone deacetylase inhibitor treatment increases coronary t-PA release in a porcine ischemia model. [PDF]
PLoS ONE, 2014 BACKGROUND: The expression of the tissue plasminogen activator gene can be affected by histone deacetylation inhibition and thus appears to be under epigenetic control.
Kristina Svennerholm +6 more
doaj +1 more source
Clinical and Applied Thrombosis/Hemostasis, 2023 Background Vitamin D deficiency has recently been suggested as an independent risk factor for thrombosis. Notably, vitamin D deficiency is common in pregnant populations, whom already have an increased thrombotic risk.
Matilde Kanstrup Andersen BA +6 more
doaj +1 more source